Bachelor of Medical Science (Hons I), UNSW Sydney
PhD, University of Sydney
Dr Alvin Kamili is a senior research officer and preclinical drug testing core team coordinator in the Zero Childhood Cancer - Personalised Medicine Program at the Children’s Cancer Institute, Sydney, Australia. He mainly focuses on the establishment of preclinical models for neuroblastoma, a disease in which patients frequently relapse with incurable, drug resistant disease, resulting in long-term survival rates below 50%. His works aim to implement personalised medicine approach to improve patient survival rates through identifying molecular aberration underlying cancer progression in individual patient, screening ex vivo tumour cells against library of anticancer drugs, and developing improved pre-clinical testing models.
NHMRC Ideas Grant, 2020-2021, $286,900, Improving induction therapy for high-risk neuroblastoma through bypass or inhibition of P-glycoprotein (APP1182974)